Which has better valuation and earnings, TYRA or AGMB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tyra Biosciences N/A N/A -$119.95M -$2.40 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Is TYRA or AGMB more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tyra Biosciences N/A -46.39% -43.07% AgomAb Therapeutics N/A N/A N/A

Does the media refer more to TYRA or AGMB?

In the previous week, AgomAb Therapeutics had 14 more articles in the media than Tyra Biosciences. MarketBeat recorded 17 mentions for AgomAb Therapeutics and 3 mentions for Tyra Biosciences. AgomAb Therapeutics' average media sentiment score of 1.31 beat Tyra Biosciences' score of 0.61 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AgomAb Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, AGMB or DMRA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A

Is AGMB or DMRA more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86%

Which has better valuation and earnings, AGMB or REPL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Replimune Group N/A N/A -$313.94M -$3.15 N/A

Is AGMB or REPL more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Replimune Group N/A -159.32% -90.84%

Does the media favor AGMB or REPL?

In the previous week, AgomAb Therapeutics had 12 more articles in the media than Replimune Group. MarketBeat recorded 17 mentions for AgomAb Therapeutics and 5 mentions for Replimune Group. AgomAb Therapeutics' average media sentiment score of 1.31 beat Replimune Group's score of 0.70 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, MNKD or AGMB?

MannKind has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 2.81 $5.86M -$0.13 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Is MNKD or AGMB more profitable?

AgomAb Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. Company Net Margins Return on Equity Return on Assets MannKind -11.08% N/A -6.31% AgomAb Therapeutics N/A N/A N/A

Does the media prefer MNKD or AGMB?

In the previous week, AgomAb Therapeutics had 3 more articles in the media than MannKind. MarketBeat recorded 17 mentions for AgomAb Therapeutics and 14 mentions for MannKind. AgomAb Therapeutics' average media sentiment score of 1.31 beat MannKind's score of 0.62 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive AgomAb Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, TRAX or AGMB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Is TRAX or AGMB more profitable?

Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A AgomAb Therapeutics N/A N/A N/A

Does the media prefer TRAX or AGMB?

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 19 mentions for First Tracks Biotherapeutics and 17 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 1.31 beat First Tracks Biotherapeutics' score of 0.59 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment First Tracks Biotherapeutics 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive AgomAb Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AgomAb Therapeutics (AGMB) Competitors

$8.67 -0.14 (-1.58%)

As of 11:34 AM Eastern

Compare

AGMB vs. TYRA, DMRA, REPL, MNKD, and TRAX

Should you buy AgomAb Therapeutics stock or one of its competitors? AgomAb Therapeutics's main competitors and comparable companies include Tyra Biosciences (TYRA), Damora Therapeutics, Inc. Common Stock (DMRA), Replimune Group (REPL), MannKind (MNKD), and First Tracks Biotherapeutics (TRAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AgomAb Therapeutics compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

In the previous week, AgomAb Therapeutics had 14 more articles in the media than Tyra Biosciences. MarketBeat recorded 17 mentions for AgomAb Therapeutics and 3 mentions for Tyra Biosciences. AgomAb Therapeutics' average media sentiment score of 1.31 beat Tyra Biosciences' score of 0.61 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AgomAb Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AgomAb Therapeutics' return on equity of 0.00% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
AgomAb Therapeutics	N/A	N/A	N/A

84.1% of Tyra Biosciences shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

Tyra Biosciences presently has a consensus price target of $47.20, indicating a potential upside of 154.31%. AgomAb Therapeutics has a consensus price target of $37.50, indicating a potential upside of 325.65%. Given AgomAb Therapeutics' higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

AgomAb Therapeutics beats Tyra Biosciences on 6 of the 11 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

AgomAb Therapeutics (NASDAQ:AGMB) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, AgomAb Therapeutics had 13 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 17 mentions for AgomAb Therapeutics and 4 mentions for Damora Therapeutics, Inc. Common Stock. AgomAb Therapeutics' average media sentiment score of 1.31 beat Damora Therapeutics, Inc. Common Stock's score of 0.60 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

AgomAb Therapeutics' return on equity of 0.00% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

AgomAb Therapeutics presently has a consensus target price of $37.50, indicating a potential upside of 325.65%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $46.50, indicating a potential upside of 150.54%. Given AgomAb Therapeutics' higher probable upside, research analysts clearly believe AgomAb Therapeutics is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

AgomAb Therapeutics beats Damora Therapeutics, Inc. Common Stock on 6 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Replimune Group?

AgomAb Therapeutics (NASDAQ:AGMB) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

92.5% of Replimune Group shares are held by institutional investors. 5.4% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, AgomAb Therapeutics had 12 more articles in the media than Replimune Group. MarketBeat recorded 17 mentions for AgomAb Therapeutics and 5 mentions for Replimune Group. AgomAb Therapeutics' average media sentiment score of 1.31 beat Replimune Group's score of 0.70 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AgomAb Therapeutics presently has a consensus price target of $37.50, suggesting a potential upside of 325.65%. Replimune Group has a consensus price target of $12.00, suggesting a potential downside of 0.91%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

AgomAb Therapeutics' return on equity of 0.00% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Replimune Group	N/A	-159.32%	-90.84%

Summary

AgomAb Therapeutics beats Replimune Group on 8 of the 11 factors compared between the two stocks.

How does AgomAb Therapeutics compare to MannKind?

MannKind (NASDAQ:MNKD) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

AgomAb Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	N/A	-6.31%
AgomAb Therapeutics	N/A	N/A	N/A

MannKind currently has a consensus price target of $7.84, indicating a potential upside of 157.17%. AgomAb Therapeutics has a consensus price target of $37.50, indicating a potential upside of 325.65%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

49.6% of MannKind shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, AgomAb Therapeutics had 3 more articles in the media than MannKind. MarketBeat recorded 17 mentions for AgomAb Therapeutics and 14 mentions for MannKind. AgomAb Therapeutics' average media sentiment score of 1.31 beat MannKind's score of 0.62 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
AgomAb Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	2.81	$5.86M	-$0.13	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

Summary

AgomAb Therapeutics beats MannKind on 6 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to First Tracks Biotherapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
AgomAb Therapeutics	N/A	N/A	N/A

First Tracks Biotherapeutics currently has a consensus target price of $67.67, suggesting a potential upside of 113.59%. AgomAb Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 325.65%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 19 mentions for First Tracks Biotherapeutics and 17 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 1.31 beat First Tracks Biotherapeutics' score of 0.59 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
AgomAb Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AgomAb Therapeutics beats First Tracks Biotherapeutics on 3 of the 5 factors compared between the two stocks.

Get AgomAb Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGMB vs. The Competition

Export

Metric	AgomAb Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$315.87M	$3.88B	$7.25B	$13.04B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	13.03	275.44	25.51
Price / Sales	N/A	1,148.01	562.05	79.58
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	N/A	16.75	10.64	6.00
Net Income	-$70.77M	-$22.65M	$3.49B	$380.50M
7 Day Performance	-1.47%	-4.89%	-3.21%	-3.35%
1 Month Performance	-29.39%	-12.84%	-7.65%	-6.23%
1 Year Performance	N/A	7.43%	2.92%	-3.96%

AgomAb Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGMB AgomAb Therapeutics	3.902 of 5 stars	$8.67 -1.6%	$37.50 +332.5%	N/A	$315.87M	N/A	N/A	62	Positive News
TYRA Tyra Biosciences	3.1884 of 5 stars	$20.24 -3.3%	$47.20 +133.2%	+29.2%	$1.25B	N/A	N/A	87
DMRA Damora Therapeutics, Inc. Common Stock	3.2215 of 5 stars	$19.55 -3.3%	$46.50 +137.9%	+45.6%	$1.25B	N/A	N/A	40	Analyst Upgrade
REPL Replimune Group	1.0958 of 5 stars	$13.25 +0.8%	$12.00 -9.4%	+165.6%	$1.23B	N/A	N/A	465
MNKD MannKind	3.6911 of 5 stars	$3.71 -2.9%	$8.34 +124.9%	-40.2%	$1.23B	$348.97M	N/A	592

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGMB) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. TYRA, DMRA, REPL, MNKD, and TRAX

How does AgomAb Therapeutics compare to Tyra Biosciences?

Summary

How does AgomAb Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does AgomAb Therapeutics compare to Replimune Group?

Summary

How does AgomAb Therapeutics compare to MannKind?

Summary

How does AgomAb Therapeutics compare to First Tracks Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. TYRA, DMRA, REPL, MNKD, and TRAX

How does AgomAb Therapeutics compare to Tyra Biosciences?

Does the media refer more to TYRA or AGMB?

Is TYRA or AGMB more profitable?

Do insiders & institutionals believe in TYRA or AGMB?

Which has better valuation and earnings, TYRA or AGMB?

Do analysts prefer TYRA or AGMB?

Summary

How does AgomAb Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Does the media prefer AGMB or DMRA?

Which has preferable valuation and earnings, AGMB or DMRA?

Is AGMB or DMRA more profitable?

Do analysts prefer AGMB or DMRA?

Do institutionals & insiders have more ownership in AGMB or DMRA?

Summary

How does AgomAb Therapeutics compare to Replimune Group?

Which has better valuation and earnings, AGMB or REPL?

Do institutionals and insiders hold more shares of AGMB or REPL?

Does the media favor AGMB or REPL?

Do analysts prefer AGMB or REPL?

Is AGMB or REPL more profitable?

Summary

How does AgomAb Therapeutics compare to MannKind?

Is MNKD or AGMB more profitable?

Do analysts recommend MNKD or AGMB?

Do insiders & institutionals believe in MNKD or AGMB?

Does the media prefer MNKD or AGMB?

Which has stronger valuation and earnings, MNKD or AGMB?

Summary

How does AgomAb Therapeutics compare to First Tracks Biotherapeutics?

Which has preferable earnings & valuation, TRAX or AGMB?

Is TRAX or AGMB more profitable?

Do analysts prefer TRAX or AGMB?

Does the media prefer TRAX or AGMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools